Sonoma Pharmaceuticals, INC

Sonoma Pharmaceuticals has increased the aggregate offering price for its common stock under an At Market Issuance Sales Agreement to $3,641,703.

Sonoma Pharmaceuticals has closed a public offering of common stock and warrants, raising approximately $3.5 million in net proceeds.

Sonoma Pharmaceuticals, Inc. has entered into a significant Manufacturing and Supply Agreement with Kenvue Brands LLC for the sale of Microcyn technology-based products in the United States.

Sonoma Pharmaceuticals announces Dr. Jay Birnbaum's retirement from its Board, replaced by experienced financial executive Ms. Vanessa Jacoby, alongside updates to director compensation.

Sonoma Pharmaceuticals highlights significant revenue growth, improved financial performance, and strategic market expansion in its latest investor presentation.

Sonoma Pharmaceuticals, Inc. announced its annual equity grant to employees, including executive officers and non-employee directors, aimed at retention and recognition.

Sonoma Pharmaceuticals, Inc. announced a 60% year-over-year revenue increase for the first quarter ended June 30, 2026, driven by strong international sales and improved gross profit margins.

Sonoma Pharmaceuticals reports increased revenue and reduced net loss for Q3 2026, but faces substantial doubt about its ability to continue as a going concern.

Sonoma Pharmaceuticals, Inc. reported significant revenue growth in its latest quarter, but faces substantial doubt about its ability to continue as a going concern due to ongoing losses and cash burn.

Sonoma Pharmaceuticals, Inc. reported increased revenue but a wider net loss and significant cash burn, raising substantial doubt about its ability to continue as a going concern.

Sonoma Pharmaceuticals reports increased revenue for Q3 2025 but acknowledges ongoing material weaknesses in internal control over financial reporting.

Sonoma Pharmaceuticals experienced revenue growth in the second quarter of fiscal year 2025, but continues to operate at a loss, with ongoing efforts to improve financial controls.

Sonoma Pharmaceuticals, Inc. announced its fiscal year 2026 results, highlighting a 37% increase in total revenue to $19.5 million, driven by strong performance in the United States and international markets.

Sonoma Pharmaceuticals, Inc. reported a net loss of $3.457 million for fiscal year 2025, despite a 12% increase in total revenue to $14.288 million, raising substantial doubt about its ability to continue as a going concern.

Sonoma Pharmaceuticals' 10-K filing reveals continued losses, a need for additional capital, and ongoing efforts to expand product reach and reduce costs.

Philippe Weigerstorfer, a Director at Sonoma Pharmaceuticals, Inc., has been granted 10,000 stock options with an exercise price of $1.26.

Amy Trombly, CEO of Sonoma Pharmaceuticals, was granted 10,000 restricted stock units.

John McLaughlin, a Director at Sonoma Pharmaceuticals, Inc., acquired 10,000 stock options with an exercise price of $1.26.

Director Vanessa Jacoby was granted 10,000 stock options in Sonoma Pharmaceuticals, Inc. on July 9, 2026, with a vesting schedule tied to service and potential change of control.

Jerome J. Dvonch, Chief Financial Officer of Sonoma Pharmaceuticals, Inc., was granted 10,000 Restricted Stock Units (RSUs) on July 9, 2026.

John Dal Poggetto, Controller at Sonoma Pharmaceuticals, Inc., reported the acquisition of 7,500 Restricted Stock Units (RSUs) on July 9, 2026.

Sonoma Pharmaceuticals, Inc. has issued its proxy statement for the 2026 Annual Stockholders Meeting, scheduled for September 16, 2026, detailing proposals for director elections, executive compensation, and auditor ratification.

Sonoma Pharmaceuticals, Inc. is holding a special meeting of stockholders on June 24, 2026, to vote on a proposal to reincorporate the company from Delaware to Nevada, citing potential cost savings and enhanced director/officer liability protections.

Sonoma Pharmaceuticals, Inc. has released its definitive proxy statement outlining proposals for its 2025 Annual Stockholders Meeting, including director election, advisory vote on executive compensation, and auditor ratification, alongside detailed compensation and governance disclosures.

Sonoma Pharmaceuticals is actively seeking stockholder participation for a crucial proposal requiring a quorum at the upcoming Annual Meeting on August 23, 2024.

Sonoma Pharmaceuticals has adjourned its Annual Meeting of Stockholders until August 23, 2024, due to the absence of a quorum.

Sonoma Pharmaceuticals is urging stockholders to vote their shares promptly for the upcoming annual meeting on August 14, 2024, emphasizing the importance of achieving a quorum.

Sonoma Pharmaceuticals has filed a registration statement for a public offering of units consisting of common stock and warrants to raise approximately $5 million.